Franklin Resources Inc. Grows Holdings in Prestige Consumer Healthcare Inc. $PBH

Franklin Resources Inc. raised its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 51.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 33,476 shares of the company’s stock after buying an additional 11,429 shares during the period. Franklin Resources Inc.’s holdings in Prestige Consumer Healthcare were worth $2,673,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. UMB Bank n.a. increased its position in shares of Prestige Consumer Healthcare by 81.8% during the second quarter. UMB Bank n.a. now owns 320 shares of the company’s stock worth $26,000 after acquiring an additional 144 shares during the last quarter. Bank of Montreal Can increased its holdings in Prestige Consumer Healthcare by 2.0% during the 2nd quarter. Bank of Montreal Can now owns 9,351 shares of the company’s stock worth $747,000 after purchasing an additional 182 shares during the last quarter. Resona Asset Management Co. Ltd. increased its holdings in Prestige Consumer Healthcare by 2.3% during the 1st quarter. Resona Asset Management Co. Ltd. now owns 9,105 shares of the company’s stock worth $783,000 after purchasing an additional 203 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its position in shares of Prestige Consumer Healthcare by 312.5% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock valued at $26,000 after purchasing an additional 250 shares in the last quarter. Finally, Alliance Wealth Advisors LLC UT boosted its stake in shares of Prestige Consumer Healthcare by 2.2% during the 1st quarter. Alliance Wealth Advisors LLC UT now owns 11,783 shares of the company’s stock valued at $1,013,000 after buying an additional 254 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on PBH shares. Oppenheimer dropped their price target on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a research note on Tuesday, October 21st. Zacks Research raised shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th. Wall Street Zen lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Sidoti raised shares of Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price target on the stock in a research report on Wednesday, September 24th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, Prestige Consumer Healthcare has an average rating of “Moderate Buy” and an average price target of $85.33.

Prestige Consumer Healthcare Stock Up 1.0%

Shares of NYSE:PBH opened at $60.29 on Thursday. The company’s fifty day moving average is $61.10 and its two-hundred day moving average is $70.14. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.51 and a current ratio of 3.70. Prestige Consumer Healthcare Inc. has a 1-year low of $57.25 and a 1-year high of $90.04. The stock has a market capitalization of $2.90 billion, a price-to-earnings ratio of 14.96, a price-to-earnings-growth ratio of 1.88 and a beta of 0.39.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, November 6th. The company reported $1.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.97 by $0.10. The business had revenue of $274.11 million during the quarter, compared to the consensus estimate of $257.14 million. Prestige Consumer Healthcare had a net margin of 18.09% and a return on equity of 12.43%. The company’s revenue for the quarter was down 3.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.09 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. Equities analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Insider Activity at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 719 shares of the stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $60.00, for a total transaction of $43,140.00. Following the sale, the vice president directly owned 42,329 shares in the company, valued at approximately $2,539,740. This represents a 1.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.40% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.